Hemogenyx Pharmaceuticals PLC Presentation at NY Stem Cell Foundation conference
October 21 2019 - 2:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
21 October 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Presentation at New York Stem Cell Foundation conference
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce
that it will present at the New York Stem Cell Foundation (NYSCF)
conference. The conference will be held on October 22-23 at The
Rockefeller University, New York
(https://nyscf.org/events/conference/).
Hemogenyx's poster presentation is entitled 'Efficacy of
FLT3-CD3 bispecific antibody against AML in humanized mouse
models'. The presentation will highlight the unique properties of
Hemogenyx's main product candidate CDX bispecific antibody that is
being developed by the Company for the treatment of
relapsed/refractory acute myeloid leukemia (AML) and conditioning
of bone marrow transplants. It will also demonstrate the utility of
the humanized mice developed by Immugenyx, LLC, a wholly-owned
subsidiary of Hemogenyx, in drug development.
The NYSCF Conference is the leading scientific meeting on
translational stem cell research. It convenes over 500 participants
from academia, industry, government, non-profits, and patient
groups. This year's keynote speeches will be given by Nobel
Laureate Shinya Yamanaka, MD, PhD, of Kyoto University and Hans
Clevers, MD, PhD, of Hubrecht Institute, Utrecht University.
Additional speakers include world-renowned, multi-disciplinary
scientists who will present their latest findings about the
transformative impact of stem cell research on numerous diseases
with high unmet needs.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan
Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
at its state-of-the-art research facility in New York City and a
wholly-owned Belgian subsidiary, Hemogenyx-Cell SPRL, located in
Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAMPBATMBIBBBL
(END) Dow Jones Newswires
October 21, 2019 02:00 ET (06:00 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Aug 2023 to Aug 2024